Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Total Equity : $30.04 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Total Equity?

Freeline Therapeutics Holdings's total equity for the quarter that ended in Sep. 2023 was $30.04 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Freeline Therapeutics Holdings Total Equity Historical Data

The historical data trend for Freeline Therapeutics Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Total Equity Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Total Equity

22.97

84.96

249.80

120.44

52.41

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Equity	Get a 7-Day Free Trial													68.58	52.41	55.99	42.02	30.04

Freeline Therapeutics Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Freeline Therapeutics Holdings's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2022 )	-	Total Liabilities(Q: Dec. 2022 )
	=	86.641	-	34.227
	=	52.41

Freeline Therapeutics Holdings's Total Equity for the quarter that ended in Sep. 2023 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2023 )	-	Total Liabilities(Q: Sep. 2023 )
	=	49.219	-	19.179
	=	30.04

Freeline Therapeutics Holdings Total Equity Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.